Airway diseases
State of the art session
Airway diseases
Clinical
Digital health
Are recent clinical advances leading to controversies in airway diseases?
Aims : To evaluate the use of short-acting β-2 agonist (SABA) monotherapy versus maintenance and reliever therapy (MART) and triple therapy for asthma; to describe new treatments for chronic cough; to determine the optimal endoscopic procedure for different patients with chronic obstructive pulmonary disease (COPD) and asthma; to discuss the role of artificial intelligence in asthma and COPD treatment.
Target audience :
Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Patient, Physician in Pulmonary Training
Methods :
Endoscopy and interventional pulmonology, General respiratory patient care, Physiology
09:35
How to treat asthma in 2021? Goodbye SABA, hello MART and welcome triple therapy
A. Papi(Cona, Ferrara, Italy)
COI
-
Description
2
114
09:50
New treatments for chronic cough
J. Smith(Manchester (Greater Manchester), United Kingdom)
COI
-
Description
3
115
10:05
Which endoscopic procedure to use and in what patient? Valves, coils, foam and heat in COPD and asthma
L. Pyng(Singapore, Singapore)
COI
-
Description
4
116
10:20
Will artificial intelligence really transform clinical practice? Applications in asthma and COPD
K. Kostikas(Ioannina, Greece)
COI
-
Description
5
117
10:35
Discussion and Q&A
6
118
. . .